# REGENXBIO Inc. (RGNX)

> REGENXBIO Inc. (RGNX) trades at $7.72 (+1.18%) as of 4:00:00 PM EST on Nov 4, 2026, +3.62% over the past month. Market cap is $503.68M, with 6.8 days to cover in short interest.

Canonical: https://massive.com/quote/rgnx
Data as of: 2026-11-04T21:00:00.594Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$7.72** +0.09 (+1.18%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$7.73** +0.01 (+0.06%)
As of 4:00:00 PM EST on Nov 4, 2026 · After hours

## Stock performance

How REGENXBIO Inc. (RGNX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.18% |
| 1W | +6.63% |
| 1M | +3.62% |
| YTD | -46.39% |
| 1Y | -33.51% |
| 52-wk range | $5.46 – $16.19 |

From daily closes through Nov 4, 2026.

## Key statistics

Today's trading snapshot for RGNX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $7.48 – $7.96 |
| Open | $7.72 |
| Prev close | $7.63 |
| Volume | 945.6K |
| Market cap | $503.68M |
| Shares out | 66.01M |

## Valuation and profitability ratios

Valuation and profitability ratios for REGENXBIO Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 2.89 |
| P/B | 7.02 |
| P/FCF | — |
| ROE | -273.7% |
| ROA | -50.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 3, 2026

## Insider trading

[REGENXBIO Inc. (RGNX) insider trading](https://massive.com/quote/rgnx/insider-trading.md): open-market Form 4 buys and sells by REGENXBIO Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events REGENXBIO Inc. has disclosed to the SEC on Form 8-K.

- Oct 16, 2026 · Director departure
  “On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the "Board") of REGENXBIO Inc. (the "Company") effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to focus his efforts on his new role. Mr. Mills' decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.”
- Sep 23, 2026 · Settlement agreement
  “On September 23, 2026, REGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. Patent Nos. 10,526,617 and 11,680,274 related to Sarepta’s manufacture, use, offer to sell and sale of SRP-9001 (also known as ELEVIDYS® in the U.S.).”
- Aug 25, 2026 · Director departure
  “On August 25, 2026, the Board also accepted the resignation of Jean Bennett, M.D., Ph.D. and A.N. "Jerry" Karabelas, Ph.D. from their positions as directors of the Company, effective August 25, 2026. Dr. Bennett and Dr. Karabelas will serve as advisors to the Company to assist the Board until February 2027, unless further extended.”
- Aug 24, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “the Company received communication from the U.S. Food and Drug Administration ("FDA") that the Company's Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II ("MPS II"), also known as Hunter Syndrome, was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 Biologics License Application ("BLA") in the near term.”
- Jul 20, 2026 · Underwriting agreement
  “On July 16, 2026, REGENXBIO Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the offer and sale of 10,003,889 shares of the Company's common stock.”

## RGNX short interest

How heavily RGNX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.8 |
| Short interest | 10.04M |
| Avg volume | 1.48M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## RGNX news

The latest news and headlines about REGENXBIO Inc. (RGNX).

- [Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?](https://www.zacks.com/stock/news/3023023/wall-street-analysts-see-a-214-55-upside-in-regenxbio-rgnx-can-the-stock-really-move-this-high?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3023023) · Zacks Investment Research · Nov 4, 2026 · positive sentiment
- [Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm](https://www.globenewswire.com/news-release/2026/07/13/3326432/0/en/Kuehn-Law-Encourages-Investors-of-Regenxbio-Inc-to-Contact-Law-Firm.html) · GlobeNewswire Inc. · Jul 13, 2026 · negative sentiment
- [Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development](https://www.globenewswire.com/news-release/2026/07/03/3321868/28124/en/Diabetic-Retinopathy-Pipeline-Insight-2026-Comprehensive-Analysis-of-50-Companies-and-55-Drugs-in-Development.html) · GlobeNewswire Inc. · Jul 3, 2026 · positive sentiment
- [Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape](https://www.globenewswire.com/news-release/2026/06/18/3314442/0/en/Age-related-Macular-Degeneration-Clinical-Trial-Pipeline-DelveInsight-Highlights-Major-Advances-Transformative-Therapies-and-90-Leading-Players-Wheeling-the-Therapeutics-Landscape.html) · GlobeNewswire Inc. · Jun 18, 2026 · positive sentiment
- [REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX](https://www.benzinga.com/pressreleases/26/04/n51821541/regenxbio-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Apr 14, 2026 · negative sentiment

## About REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 371 |
| Listed | Sep 17, 2015 |

[Company website](https://www.regenxbio.com)

## FAQ

### What is the REGENXBIO Inc. (RGNX) stock price today?

REGENXBIO Inc. (RGNX) is trading at $7.72 (+1.18% on the day) as of 4:00:00 PM EST on Nov 4, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is REGENXBIO Inc.?

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins.

### What is the short interest in RGNX?

As of Oct 15, 2026, RGNX has 10.04M shares short and 6.8 days to cover.

### What exchange is RGNX listed on?

REGENXBIO Inc. (RGNX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time RGNX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=RGNX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [REGENXBIO Inc. (RGNX) insider trading](https://massive.com/quote/rgnx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms